457 related articles for article (PubMed ID: 19914330)
1. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease.
Padurariu M; Ciobica A; Hritcu L; Stoica B; Bild W; Stefanescu C
Neurosci Lett; 2010 Jan; 469(1):6-10. PubMed ID: 19914330
[TBL] [Abstract][Full Text] [Related]
2. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609
[TBL] [Abstract][Full Text] [Related]
3. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
Hernanz A; De la Fuente M; Navarro M; Frank A
Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
[TBL] [Abstract][Full Text] [Related]
4. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
5. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
Galimberti D; Fenoglio C; Lovati C; Venturelli E; Guidi I; Corrà B; Scalabrini D; Clerici F; Mariani C; Bresolin N; Scarpini E
Neurobiol Aging; 2006 Dec; 27(12):1763-8. PubMed ID: 16307829
[TBL] [Abstract][Full Text] [Related]
6. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease.
Greilberger J; Koidl C; Greilberger M; Lamprecht M; Schroecksnadel K; Leblhuber F; Fuchs D; Oettl K
Free Radic Res; 2008 Jul; 42(7):633-8. PubMed ID: 18654878
[TBL] [Abstract][Full Text] [Related]
7. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease.
Torres LL; Quaglio NB; de Souza GT; Garcia RT; Dati LM; Moreira WL; Loureiro AP; de Souza-Talarico JN; Smid J; Porto CS; Bottino CM; Nitrini R; Barros SB; Camarini R; Marcourakis T
J Alzheimers Dis; 2011; 26(1):59-68. PubMed ID: 21593563
[TBL] [Abstract][Full Text] [Related]
8. Lipids' peroxidation markers in Alzheimer's disease and vascular dementia.
Gustaw-Rothenberg K; Kowalczuk K; Stryjecka-Zimmer M
Geriatr Gerontol Int; 2010 Apr; 10(2):161-6. PubMed ID: 20446930
[TBL] [Abstract][Full Text] [Related]
9. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease.
Rombouts SA; Goekoop R; Stam CJ; Barkhof F; Scheltens P
Neuroimage; 2005 Jul; 26(4):1078-85. PubMed ID: 15961047
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment.
Mangialasche F; Polidori MC; Monastero R; Ercolani S; Camarda C; Cecchetti R; Mecocci P
Ageing Res Rev; 2009 Oct; 8(4):285-305. PubMed ID: 19376275
[TBL] [Abstract][Full Text] [Related]
11. Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia.
Puertas MC; Martínez-Martos JM; Cobo MP; Carrera MP; Mayas MD; Ramírez-Expósito MJ
Exp Gerontol; 2012 Aug; 47(8):625-30. PubMed ID: 22664577
[TBL] [Abstract][Full Text] [Related]
12. Oxidative damage in mild cognitive impairment and early Alzheimer's disease.
Lovell MA; Markesbery WR
J Neurosci Res; 2007 Nov; 85(14):3036-40. PubMed ID: 17510979
[TBL] [Abstract][Full Text] [Related]
13. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease.
Kim TS; Lim HK; Lee JY; Kim DJ; Park S; Lee C; Lee CU
Neurosci Lett; 2008 May; 436(2):196-200. PubMed ID: 18378084
[TBL] [Abstract][Full Text] [Related]
14. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Immunol Lett; 2008 May; 117(2):198-202. PubMed ID: 18367253
[TBL] [Abstract][Full Text] [Related]
15. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
16. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease.
Guidi I; Galimberti D; Lonati S; Novembrino C; Bamonti F; Tiriticco M; Fenoglio C; Venturelli E; Baron P; Bresolin N; Scarpini E
Neurobiol Aging; 2006 Feb; 27(2):262-9. PubMed ID: 16399211
[TBL] [Abstract][Full Text] [Related]
17. Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease.
Kharrazi H; Vaisi-Raygani A; Rahimi Z; Tavilani H; Aminian M; Pourmotabbed T
Clin Biochem; 2008 Aug; 41(12):932-6. PubMed ID: 18505684
[TBL] [Abstract][Full Text] [Related]
18. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease.
Ackl N; Ising M; Schreiber YA; Atiya M; Sonntag A; Auer DP
Neurosci Lett; 2005 Aug 12-19; 384(1-2):23-8. PubMed ID: 15905028
[TBL] [Abstract][Full Text] [Related]
19. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease.
Diniz BS; Teixeira AL; Ojopi EB; Talib LL; Mendonça VA; Gattaz WF; Forlenza OV
J Alzheimers Dis; 2010; 22(4):1305-11. PubMed ID: 20930310
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
Galimberti D; Schoonenboom N; Scheltens P; Fenoglio C; Bouwman F; Venturelli E; Guidi I; Blankenstein MA; Bresolin N; Scarpini E
Arch Neurol; 2006 Apr; 63(4):538-43. PubMed ID: 16606766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
